Floatz logo

Arimidex

Adjuvant Treatment

Dartmouth-Hitchcock Medical CenterPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Adjuvant Treatment cohort.

Asset / SponsorPhaseRating
Iparomlimab
The Affiliated Hospital of Xuzhou Medical University
Phase 2CCC
EXEMESTANE
Dartmouth-Hitchcock Medical Center
Phase 2CCC
TAMOXIFEN
Dartmouth-Hitchcock Medical Center
Phase 2CCC

Same molecule, other indications

Arimidex is also rated in:

hormone receptor-positive breast cancerDormant
BBB
Indicative ·
74 / 100
View asset →
hypogonadotropic hypogonadismDormant
BBB
Indicative ·
73 / 100
View asset →
invasive breast carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →